Effects of rosglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes

Osei, Kwame; Gaillard, Trudy; Kaplow, June; Bullock, Matthew; Schuster, Dara

doi:10.1016/j.metabol.2004.06.023

Cited by 40 publications

(32 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Little information is available concerning the effects of TZDs on plasma adiponectin levels in non-diabetics, and even where data were not obtained in a randomized manner (33,34). In the present study, rosiglitazone treatment markedly increased circulating adiponectin levels by 160% (P , 0.001), whereas no change was observed in the control group (P ¼ 0.21).…”

Section: Discussioncontrasting

confidence: 46%

Effect of rosiglitazone on plasma adiponectin levels and arterial stiffness in subjects with prediabetes or non-diabetic metabolic syndrome

et al. 2006

View full text Add to dashboard Cite

Objective: Thiazolidinediones have favorable influences on surrogate markers of atherosclerosis such as adiponectin, and arterial stiffness in diabetic patients. However, it is not well known whether these beneficial effects occur in subjects without diabetes, such as prediabetes or the non-diabetic metabolic syndrome (MetS). The present study was therefore designed to evaluate the effectiveness of the insulin-sensitizing agent rosiglitazone on circulating adipocytokine levels and brachial-ankle pulse wave velocity (baPWV) in non-diabetics. Design and methods: Ninety-nine subjects with prediabetes or non-diabetic MetS were randomly assigned to either rosiglitazone or an untreated control group (50 and 49 subjects respectively). The rosiglitazone group was treated daily for 12 weeks with 4 mg rosiglitazone. All subjects received a 75 g oral glucose test (OGTT) before and after treatment. In addition, baPWV, together with the levels of adiponectin, resistin, and high sensitivity C-reactive protein (hsCRP) were determined. Results: Rosiglitazone treatment significantly increased circulating adiponectin levels (P , 0.001) relative to the control group (P ¼ 0.21). Plasma resistin levels were unchanged in both the rosiglitazone-treated and -untreated groups, but baPWV and hsCRP were significantly decreased (P , 0.001 and P ¼ 0.003 respectively) in the rosiglitazone group only. Multiple linear regression analysis showed that changes in plasma adiponectin and baPWV were significantly affected by rosiglitazone treatment. Conclusions: These data suggest that rosiglitazone may have an anti-atherogenic effect in subjects with prediabetes or non-diabetic MetS.

show abstract

Section: Discussioncontrasting

confidence: 46%

Effect of rosiglitazone on plasma adiponectin levels and arterial stiffness in subjects with prediabetes or non-diabetic metabolic syndrome

et al. 2006

View full text Add to dashboard Cite

show abstract

“…22 The beneficial effect of rosiglitazone has been demonstrated in patients with type 2 diabetes and impaired glucose tolerance. 23,24 The present study demonstrated that combining rosiglitazone with metformin resulted in better control of body weight than metformin monotherapy, as well as improving β-cell function and improving serum insulin levels and insulin sensitivity. Diastolic blood pressure was also lowered, although the mechanism by which this occurred is unclear.…”

Section: Rosiglitazone In Obese Subjectsmentioning

confidence: 58%

Effects of Metformin and Rosiglitazone on Peripheral Insulin Resistance and β-Cell Function in Obesity: A Double-Blind, Randomized, Controlled Study

Zhang

et al. 2011

J Int Med Res

View full text Add to dashboard Cite

Metformin and rosiglitazone combination therapy is known to improve insulin resistance and postpone diabetes mellitus development in subjects with impaired glucose tolerance. This double-blind, randomized, controlled study assessed this combination therapy for preventing type 2 diabetes in obese subjects with hyperinsulinaemia. Subjects received metformin (500 mg three times daily, orally) plus either rosiglitazone (4 mg once daily, orally; n = 94) or placebo (n = 95) and were followed for 6 months. Blood pressure, body fat, body mass index (BMI), lipid and insulin levels were recorded preand post-treatment. Metformin plus rosiglitazone significantly decreased blood pressure, lipids, BMI, and fasting and postmeal insulin levels. Metformin plus placebo led to a significant decrease in blood pressure, BMI and lipid levels, but fasting and postmeal insulin levels were unchanged. Adverse events were similar between the two groups. The metformin and rosiglitazone combination increased insulin sensitivity and b-cell function recovered. This approach may represent a therapeutic option for preventing development of type 2 diabetes in obese subjects with hyperinsulinaemia.

show abstract

“…For example, adiponectin levels are increased by thiazolidinediones (38,39), medications that improve insulin sensitivity at the cellular level (22), so raising low adiponectin states is achievable if proven to be beneficial. Rosiglitazone therapy has been confirmed to increase adiponectin levels in African Americans with impaired glucose tolerance or diabetes (40), although direct evidence for the benefit of thiazolidinediones in human diabetic nephropathy is currently lacking.…”

Section: Discussionmentioning

confidence: 99%

Serum Adiponectin and Renal Dysfunction in Men With Type 2 Diabetes

Lin

Curhan

2007

Diabetes Care

View full text Add to dashboard Cite

OBJECTIVE -Inflammation is associated with both chronic kidney dysfunction and type 2 diabetes. Adiponectin, a novel circulating anti-inflammatory protein made by adipocytes, has been reported to be lower in diabetic than nondiabetic subjects. In contrast, serum levels of adiponectin are elevated in end-stage renal disease. We sought to investigate the relation between adiponectin and mild to moderate renal dysfunction in men with type 2 diabetes. RESULTS -Adiponectin was positively correlated with age (Spearman coefficient, r ϭ 0.19, P Ͻ 0.001) and negatively correlated with weight (Spearman coefficient, r ϭ Ϫ0.18, P Ͻ 0.001). Those with adiponectin in the second quartile or higher (Ͼ10 g/ml) compared with those in the first quartile had a reduced odds for renal dysfunction (multivariate odds ratio 0.48 [95% CI 0.28 -0.81]). These results were unchanged when serum lipids were included in the multivariate model. RESEARCH DESIGN AND METHODSCONCLUSIONS -We conclude that a higher serum adiponectin concentration is associated with reduced odds of moderate renal dysfunction in men with type 2 diabetes. Diabetes Care 30:239 -244, 2007S ystemic inflammation has been implicated in the progression of chronic kidney disease in animal models (1,2) and in humans (3,4). As the leading cause of kidney failure in the world, type 2 diabetes has been postulated to be a generalized inflammatory condition resulting from obesity-induced dysregulation of adipocytes, which produce an excess of inflammatory cytokines (5). Scientists have speculated that this persistent inflammatory state further contributes to the development of the extensive vascular disease characteristic of diabetes.Adiponectin, a recently discovered circulating 30-kDa protein exclusively secreted by adipocytes, is present at concentrations of 5-30 g/ml in healthy humans (6) and is considered to be an important modulator of insulin sensitivity (7) and dyslipidemia (8). Anti-inflammatory properties also have been attributed to adiponectin, a theory supported by observations that serum concentrations of adiponectin are inversely associated with inflammatory markers such as fibrinogen, intracellular adhesion molecule-1, Eselectin, and C-reactive protein (9,10). The observation that adiponectin may be protective against vascular disease via the above mechanisms is supported by crosssectional analyses of individuals with coronary heart disease, who have lower concentrations of adiponectin when compared with control subjects (11,12), and prospective studies revealing that higher adiponectin is associated with a decreased risk for subsequent cardiovascular disease events in nondiabetic subjects (13), type 1 diabetic subjects (14), type 2 diabetic men (15), and in end-stage renal disease patients (16). The role of adiponectin in cardiovascular disease is not definitive, however, because some studies have found no relation between adiponectin and cardiovascular disease risk (17,18).Adiponectin appears to play an important role in the pathogenesis of type 2 diabetes. Cross-s...

show abstract

Effects of rosglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes

Cited by 40 publications

References 36 publications

Effect of rosiglitazone on plasma adiponectin levels and arterial stiffness in subjects with prediabetes or non-diabetic metabolic syndrome

Effect of rosiglitazone on plasma adiponectin levels and arterial stiffness in subjects with prediabetes or non-diabetic metabolic syndrome

Effects of Metformin and Rosiglitazone on Peripheral Insulin Resistance and β-Cell Function in Obesity: A Double-Blind, Randomized, Controlled Study

Serum Adiponectin and Renal Dysfunction in Men With Type 2 Diabetes

Contact Info

Product

Resources

About